Design and Analysis of a Petri Net Model of the Von Hippel-Lindau (VHL) Tumor Suppressor Interaction Network

Von Hippel-Lindau (VHL) syndrome is a hereditary condition predisposing to the development of different cancer forms, related to germline inactivation of the homonymous tumor suppressor pVHL. The best characterized function of pVHL is the ubiquitination dependent degradation of Hypoxia Inducible Factor (HIF) via the proteasome. It is also involved in several cellular pathways acting as a molecular hub and interacting with more than 200 different proteins. Molecular details of pVHL plasticity remain in large part unknown. Here, we present a novel manually curated Petri Net (PN) model of the main pVHL functional pathways. The model was built using functional information derived from the literature. It includes all major pVHL functions and is able to credibly reproduce VHL syndrome at the molecular level. The reliability of the PN model also allowed in silico knockout experiments, driven by previous model analysis. Interestingly, PN analysis suggests that the variability of different VHL manifestations is correlated with the concomitant inactivation of different metabolic pathways.

[1]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[3]  G. Bell,et al.  Organization of the Human GLUT2 (Pancreatic β-Cell and Hepatocyte) Glucose Transporter Gene , 1993, Diabetes.

[4]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[5]  S. Vannucci,et al.  Glucose transporter proteins in brain: Delivery of glucose to neurons and glia , 1997, Glia.

[6]  O. Conneely,et al.  Neuroendocrine regulation of the hypothalamic pituitary adrenal axis by the nurr1/nur77 subfamily of nuclear receptors. , 1997, Molecular endocrinology.

[7]  J M Ward,et al.  Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  W. Linehan,et al.  Improved detection of germline mutations in the von Hippel‐Lindau disease tumor suppressor gene , 1998, Human mutation.

[9]  H. Nawata,et al.  [Functional role of nur77 family in T-cell apoptosis and stress response]. , 1998, Nihon rinsho. Japanese journal of clinical medicine.

[10]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[11]  G. Semenza,et al.  Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. , 1999, Annual review of cell and developmental biology.

[12]  L. Phillips,et al.  Involvement of Sp1 in the transcriptional regulation of the rat insulin-like growth factor-1 gene , 2000, Molecular and Cellular Endocrinology.

[13]  R. Burk,et al.  Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Thomas,et al.  An efficient and robust statistical modeling approach to discover differentially expressed genes using genomic expression profiles. , 2001, Genome research.

[15]  G. Semenza,et al.  FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. , 2001 .

[16]  A. Vortmeyer,et al.  Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion , 2002, Oncogene.

[17]  Jun O. Liu,et al.  Nur77 Activated by Hypoxia-Inducible Factor-1α Overproduces Proopiomelanocortin in von Hippel-Lindau-Mutated Renal Cell Carcinoma , 2004, Cancer Research.

[18]  Ina Koch,et al.  Model validation of biological pathways using Petri nets , 2004 .

[19]  W. Kaelin,et al.  Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  John N Weinstein,et al.  Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system. , 2004, Molecular biology of the cell.

[21]  M. Jewett,et al.  Human HIF‐3α4 is a dominant‐negative regulator of HIF‐1 and is down‐regulated in renal cell carcinoma , 2005 .

[22]  C. Koumenis,et al.  HIF-1α and p53: the ODD couple? , 2005 .

[23]  Patrick C Phillips,et al.  Network thinking in ecology and evolution. , 2005, Trends in ecology & evolution.

[24]  H. Youn,et al.  The Positive Regulation of p53 by the Tumor Suppressor VHL , 2006, Cell cycle.

[25]  Monika Heiner,et al.  Application of Petri net based analysis techniques to signal transduction pathways , 2006, BMC Bioinformatics.

[26]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[27]  R. Johnson,et al.  pVHL Function Is Essential for Endothelial Extracellular Matrix Deposition , 2006, Molecular and Cellular Biology.

[28]  Claudio R. Thoma,et al.  Priming-Dependent Phosphorylation and Regulation of the Tumor Suppressor pVHL by Glycogen Synthase Kinase 3 , 2006, Molecular and Cellular Biology.

[29]  Qi Fang Li,et al.  Hypoxia upregulates hypoxia inducible factor (HIF)-3α expression in lung epithelial cells: characterization and comparison with HIF-1α , 2006, Cell Research.

[30]  E. Almaas.  Biological impacts and context of network theory , 2007, Journal of Experimental Biology.

[31]  A. Mobasheri,et al.  Expression of glucose transporters GLUT-1, GLUT-3, GLUT-9 and HIF-1α in normal and degenerate human intervertebral disc , 2008, Histochemistry and Cell Biology.

[32]  Claudine Chaouiya,et al.  Petri net modelling of biological networks , 2007, Briefings Bioinform..

[33]  Rahul Simha,et al.  Pathway Switching Explains the Sharp Response Characteristic of Hypoxia Response Network , 2007, PLoS Comput. Biol..

[34]  Josep Tabernero,et al.  The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents , 2007, Molecular Cancer Research.

[35]  W. Krek,et al.  Multitasking by pVHL in tumour suppression. , 2007, Current opinion in cell biology.

[36]  P. Benfey,et al.  Evolution, Interactions, and Biological Networks , 2007, PLoS biology.

[37]  Thomas G. Smith,et al.  The human side of hypoxia-inducible factor , 2008, British journal of haematology.

[38]  Ina Koch,et al.  Petri net modelling of gene regulation of the Duchenne muscular dystrophy , 2008, Biosyst..

[39]  E. Cho,et al.  Nur77 upregulates HIF-α by inhibiting pVHL-mediated degradation , 2008, Experimental & Molecular Medicine.

[40]  W. Krek,et al.  pVHL: A Multipurpose Adaptor Protein , 2008, Science Signaling.

[41]  H. Moch,et al.  VHL loss causes spindle misorientation and chromosome instability , 2009, Nature Cell Biology.

[42]  Silvio C. E. Tosatto,et al.  Adding structural information to the von Hippel–Lindau (VHL) tumor suppressor interaction network , 2009, FEBS letters.

[43]  Arto Salomaa,et al.  Algorithmic Bioprocesses , 2009, Natural Computing Series.

[44]  R. Moon,et al.  Beta-catenin gets jaded and von Hippel-Lindau is to blame. , 2009, Trends in biochemical sciences.

[45]  Monika Heiner,et al.  Understanding Network Behavior by Structured Representations of Transition Invariants , 2009, Algorithmic Bioprocesses.

[46]  Monika Heiner,et al.  Structural Analysis to Determine the Core of Hypoxia Response Network , 2010, PloS one.

[47]  Monika Heiner,et al.  Snoopy - a unifying Petri net framework to investigate biomolecular networks , 2010, Bioinform..

[48]  Ralf H. Bortfeldt,et al.  Exhaustive Analysis of the Modular Structure of the Spliceosomal Assembly Network: A Petri Net Approach , 2010, Silico Biol..

[49]  Silvio C. E. Tosatto,et al.  Identification and In Silico Analysis of Novel von Hippel‐Lindau (VHL) Gene Variants from a Large Population , 2011, Annals of human genetics.

[50]  Rafael C. Jimenez,et al.  The IntAct molecular interaction database in 2012 , 2011, Nucleic Acids Res..

[51]  Silvio C. E. Tosatto,et al.  In silico investigation of PHD‐3 specific HIF1‐α proline 567 hydroxylation: A new player in the VHL/HIF‐1α interaction pathway? , 2013, FEBS letters.

[52]  K. Clarke,et al.  Differential Translocation of the Fatty Acid Transporter, FAT/CD36, and the Glucose Transporter, GLUT4, Coordinates Changes in Cardiac Substrate Metabolism During Ischemia and Reperfusion , 2013, Circulation. Heart failure.

[53]  Li Liu,et al.  A multi-layer inference approach to reconstruct condition-specific genes and their regulation , 2013, Bioinform..

[54]  T. Soga.  Cancer metabolism: Key players in metabolic reprogramming , 2013, Cancer science.